BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36971798)

  • 21. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
    Martin JA; Warner RR; Wisnivesky JP; Kim MK
    Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms.
    Beck J; Siebenhüner A; Wild D; Christ E; Refardt J
    Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38117915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study.
    Abdel-Rahman O; Fazio N
    Pancreas; 2021 May-Jun 01; 50(5):727-731. PubMed ID: 34016894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.
    Borbath I; Garcia-Carbonero R; Bikmukhametov D; Jimenez-Fonseca P; Castaño A; Barkmanova J; Sedlackova E; Kollár A; Christ E; Kaltsas G; Kos-Kudla B; Maasberg S; Verslype C; Pape UF
    Eur J Cancer; 2022 Jun; 168():80-90. PubMed ID: 35472579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
    Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
    J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms.
    Mandal R; Hardin H; Baus R; Rehrauer W; Lloyd RV
    Endocr Pathol; 2017 Dec; 28(4):345-350. PubMed ID: 29032398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
    Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
    Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme.
    Yin XN; Shen CY; Yin YQ; Chen HJ; Chen HN; Yin Y; Han LY; Chen JJ; Tang SM; Chen ZX; Zhang B
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e37-e44. PubMed ID: 28856815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary malignancy in patients with sporadic neuroendocrine neoplasia.
    Krausch M; Raffel A; Anlauf M; Schott M; Lehwald N; Krieg A; Kröpil F; Cupisti K; Knoefel WT
    Endocrine; 2013 Oct; 44(2):510-6. PubMed ID: 23494366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
    Zhu LM; Tang L; Qiao XW; Wolin E; Nissen NN; Dhall D; Chen J; Shen L; Chi Y; Yuan YZ; Ben QW; Lv B; Zhou YR; Bai CM; Chen J; Song YL; Song TT; Lu CM; Yu R; Chen YJ
    Medicine (Baltimore); 2016 Feb; 95(7):e2836. PubMed ID: 26886644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Boyar Cetinkaya R; Aagnes B; Myklebust TÅ; Thiis-Evensen E
    Int J Cancer; 2018 Mar; 142(6):1139-1147. PubMed ID: 29082524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.